National Institutes of Health, Johns Hopkins
University Mark Partnership for New Biomedical Research Center
The National Institutes of Health (NIH) and The Johns Hopkins University
marked a key milestone in their long partnership to advance scientific
discovery today, commemorating the beginning of construction of
a new Biomedical Research Center (BRC) on the Johns Hopkins Bayview
campus in Baltimore, Maryland. The BRC, which is slated for occupancy
in the fall of 2006, will house major components of the intramural
research programs of the National Institute on Aging (NIA) and the
National Institute on Drug Abuse (NIDA).
“I am extremely pleased that this collaborative effort is
moving forward,” said NIH Director Elias A. Zerhouni, M.D.
“New advances at the Biomedical Research Center could have
major implications for the millions of Americans who suffer from
aging-related disease and disability, and from the consequences
of drug abuse and addiction.”
Once completed, the BRC will consist of approximately 500,000 gross
square feet of laboratory, vivarium and administrative space, and
will house nearly 1,000 scientists and support staff for both basic
and clinical research programs. At today’s construction kick-off,
representatives from NIH and Johns Hopkins as well as officials
from the City of Baltimore, the State of Maryland, and the U.S.
Congress took stock of the collaborative nature of the project,
and its promise for furthering research innovations.
At the NIA, researchers in the new facility will continue their
work in a range of areas, including studies of normal aging as a
risk factor for heart disease at older ages; animal studies of caloric
restrictions in the development and potential prevention of disease;
and investigations of stability of personality in adulthood and
later.
“Like our colleagues at Johns Hopkins and NIDA, we are pleased
that this new building is becoming a reality after much thought
and planning,” noted Richard J. Hodes, M.D., Director of the
NIA. “We anticipate that it will be a dynamic environment
which will foster significant basic and clinical research into the
many conditions associated with aging.”
Scientists at the NIDA who will occupy the BRC plan to pursue research
directions related to the identification of genes that contribute
to drug addiction; development and use of neuroimaging techniques such as PET, MRI and functional
MRI to better understand the neurological components that
contribute to drug abuse, addiction, and other compulsive disorders;
and the exploration of effective treatments for adolescent smokers,
particularly in minority populations.
“NIDA is delighted that our intramural research program will
be moving into this state-of-the-art facility,” said Nora
D. Volkow, M.D., Director of the NIDA. “It will allow us to
continue to develop and use neuroimaging and other novel technologies
to learn more about preventing and treating drug addiction.”
The National Institutes of Health (NIH), an agency of the U.S.
Department of Health and Human Services, is the primary Federal
agency for conducting and supporting basic, clinical, and translational
medical research. NIH is comprised of 27 institutes and centers
and investigates the causes, treatments, and cures for both common
and rare diseases.
|